EUVIMEDEUVIMED entdecken
Systematische Übersicht

The role of β‐adrenergic receptors in the regulation of cardiac tolerance to ischemia/reperfusion. Why do β‐adrenergic receptor agonists and antagonists protect the heart?

Leonid N Maslov iD, Natalia V Naryzhnaya iD, Nikita S Voronkov, Boris K Kurbatov, Ivan A Derkachev, Vyacheslav V Ryabov, Evgeny V Vyshlov, Viktor V Kolpakov, Eugenia A Tomilova, Ekaterina V Sapozhenkova, Nirmal Singh iD, Feng Fu und 1 weitere

Fundamental & Clinical Pharmacology · 2024

DOI: 10.1111/fcp.12988 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Fundamental & Clinical Pharmacology, 2024. Verfasst von Leonid N Maslov und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Research Institute, Tomsk National Research Medical Centre, Russian Academy of Sciences, Tomsk, Russia. Hauptthemen laut MEDLINE: Adrenergic beta-Antagonists, Myocardial Reperfusion Injury, Receptors, Adrenergic, beta. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 120 Literaturangaben. Gefördert von: Ministry of Science and Higher Education of the Russian Federation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Catecholamines and β‐adrenergic receptors (β‐ARs) play an important role in the regulation of cardiac tolerance to the impact of ischemia and reperfusion. This systematic review analyzed the molecular mechanisms of the cardioprotective activity of β‐AR ligands.

Methods

We performed an electronic search of topical articles using PubMed databases from 1966 to 2023. We cited original in vitro and in vivo studies and review articles that documented the cardioprotective properties of β‐AR agonists and antagonists.

Results

The infarct‐reducing effect of β‐AR antagonists did not depend on a decrease in the heart rate. The target for β‐blockers is not only cardiomyocytes but also neutrophils. β1‐blockers (metoprolol, propranolol, timolol) and the selective β2‐AR agonist arformoterol have an infarct‐reducing effect in coronary artery occlusion (CAO) in animals. Antagonists of β1‐ and β2‐АR (metoprolol, propranolol, nadolol, carvedilol, bisoprolol, esmolol) are able to prevent reperfusion cardiac injury. All β‐AR ligands that reduced infarct size are the selective or nonselective β1‐blockers. It was hypothesized that β1‐AR blocking promotes an increase in cardiac tolerance to I/R. The activation of β1‐AR, β2‐AR, and β3‐AR can increase cardiac tolerance to I/R. The cardioprotective effect of β‐AR agonists is mediated via the activation of kinases and reactive oxygen species production.

Conclusions

It is unclear why β‐blockers with the similar receptor selectivity have the infarct‐sparing effect while other β‐blockers with the same selectivity do not affect infarct size. What is the molecular mechanism of the infarct‐reducing effect of β‐blockers in reperfusion? Why did in early studies β‐blockers decrease the mortality rate in patients with acute myocardial infarction (AMI) and without reperfusion and in more recent studies β‐blockers had no effect on the mortality rate in patients with AMI and reperfusion? The creation of more effective β‐AR ligands depends on the answers to these questions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenergic beta-AntagonistsMyocardial Reperfusion InjuryReceptors, Adrenergic, betaAnimalsHumansAdrenergic beta-AgonistsCardiotonic Agents

Stichwörter der Autor:innen

acute myocardial infarctioncoronary artery bypass graftingheartneutrophilsβ‐adrenergic receptor agonistsβ‐adrenergic receptor antagonists

Substanzen

Adrenergic beta-AntagonistsReceptors, Adrenergic, betaAdrenergic beta-AgonistsCardiotonic Agents

Autor:innen und Institutionen

  • Cardiology Research Institute, Tomsk National Research Medical Centre, Russian Academy of Sciences, Tomsk, Russia.
  • Tyumen State Medical University, Tyumen, Russia.
  • Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India.
  • Department of Physiology and Pathophysiology, National Key Discipline of Cell Biology, School of Basic Medicine, Fourth Military Medical University, Xi'an, China.

ORCID-Profile: Leonid N Maslov, Natalia V Naryzhnaya, Nirmal Singh

Förderung

  • Ministry of Science and Higher Education of the Russian Federation

Zitieren

APA

Maslov, L. N., Naryzhnaya, N. V., Voronkov, N. S., Kurbatov, B. K., Derkachev, I. A., Ryabov, V. V., Vyshlov, E. V., Kolpakov, V. V., Tomilova, E. A., Sapozhenkova, E. V., Singh, N., Fu, F., & Pei, J. (2024). The role of β‐adrenergic receptors in the regulation of cardiac tolerance to ischemia/reperfusion. Why do β‐adrenergic receptor agonists and antagonists protect the heart?. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.12988

Vancouver

Maslov LN, Naryzhnaya NV, Voronkov NS, Kurbatov BK, Derkachev IA, Ryabov VV, et al. The role of β‐adrenergic receptors in the regulation of cardiac tolerance to ischemia/reperfusion. Why do β‐adrenergic receptor agonists and antagonists protect the heart?. Fundamental & Clinical Pharmacology. 2024. doi:10.1111/fcp.12988

BibTeX
@article{Maslov2024,
  author = {Maslov, Leonid N and Naryzhnaya, Natalia V and Voronkov, Nikita S and Kurbatov, Boris K and Derkachev, Ivan A and Ryabov, Vyacheslav V and Vyshlov, Evgeny V and Kolpakov, Viktor V and Tomilova, Eugenia A and Sapozhenkova, Ekaterina V and Singh, Nirmal and Fu, Feng and Pei, Jianming},
  title = {The role of β‐adrenergic receptors in the regulation of cardiac tolerance to ischemia/reperfusion. Why do β‐adrenergic receptor agonists and antagonists protect the heart?},
  journal = {Fundamental & Clinical Pharmacology},
  year = {2024},
  doi = {10.1111/fcp.12988}
}
Kostenlos starten →